Abstract: A RIO device mounted to a train includes an output unit that outputs a signal to a relay mounted to the train, and a controller that controls whether or not to cause the output unit to output the signal. The output unit includes a readback circuit that detects whether or not the signal is outputted from the output unit. The controller makes a signal stop request and a signal output request to the output unit before operation of the train starts, acquires a detection result of the readback circuit while each of the signal stop request and the signal output request is performed, and detects abnormality of the output unit using the detection result.

Abstract: The present application provides a semi-permeable hydrogel composition comprising an alginate matrix that is covalently crosslinked in its periphery to a multi-armed water soluble polymer, along with related methods and uses thereof.

Abstract: The present application provides a semi-permeable hydrogel composition comprising an alginate matrix that is covalently crosslinked in its periphery to a multi-armed water soluble polymer, along with related methods and uses thereof.

Abstract: The present application provides a semi-permeable hydrogel composition comprising an alginate matrix that is covalently crosslinked in its periphery to a multi-armed water soluble polymer, along with related methods and uses thereof.

Abstract: Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same.

Abstract: Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same.

Abstract: Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same.

Abstract: Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same.

Abstract: Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same.

Abstract: A process for producing a sustained-release composition which comprises mixing an aqueous solution containing a physiologically active substance and an acid or base in a molar amount of 1.5 or more times that of the physiologically active substance with a solution of a biodegradable polymer and then drying the mixture is provided.

Abstract: Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same.

Abstract: An electrical connector is provided for mounting on a circuit board and includes a dielectric housing mounting a plurality of first terminals having circuit board press-fit portions projecting therefrom. A plurality of second terminals are mounted on the housing and have circuit board press-fit portions projecting therefrom. A press-fitting block is engageable with the housing and is locked to the first terminals for press-fitting the first terminals into holes in the circuit board. The press-fit portions of the second terminals are exposed exteriorly of the housing and the press-fitting block for locking engagement by an appropriate independent pressfitting jig for press-fitting the second terminals into holes in the circuit board.

Abstract: A sustained release preparation comprising a combination of a microcapsule which gradually releases a GnRH agonist or a salt thereof for a long term, and a microcapsule which gradually releases a GnRH agonist or a salt thereof for a short term.

Abstract: An electrical connector is provided for mounting on a circuit board and includes a dielectric housing mounting a plurality of first terminals having circuit board press-fit portions projecting therefrom. A plurality of second terminals are mounted on the housing and have circuit board press-fit portions projecting therefrom. A press-fitting block is engageable with the housing and is locked to the first terminals for press-fitting the first terminals into holes in the circuit board. The press-fit portions of the second terminals are exposed exteriorly of the housing and the press-fitting block for locking engagement by an appropriate independent pressfitting jig for press-fitting the second terminals into holes in the circuit board.

Abstract: A sustained release preparation comprising a combination of a microcapsule which gradually releases a GnRH agonist or a salt thereof for a long term, and a microcapsule which gradually releases a GnRH agonist or a salt thereof for a short term.

Abstract: A process for producing a sustained-release composition which comprises mixing an aqueous solution containing a physiologically active substance and an acid or base in a molar amount of 1.5 or more times that of the physiologically active substance with a solution of a biodegradable polymer and then drying the mixture is provided.

Abstract: Sustained-release medicines comprising (A) an angiotensin II antagonist combined with (B) one or more drugs selected from among remedies for hypertension, hypoglycemics, remedies for hyperlipemia, antithromboties, remedies for menopause and anticancer drugs. Using these medicines, remarkably excellent effects can be achieved compared with the case of using each active ingredient alone, which makes it possible to lessen the administration dose and relieve side effects.

Abstract: The present invention provides a pharmaceutical preparation which is safe, little irritate subjects and comprises a water-insoluble or hardly water-soluble drug at a high level, and a simple and convenient process for producing the preparation. A process for producing a pharmaceutical composition comprising a water-insoluble or hardly water-soluble drug coated with phospholipid, said process comprising mixing a solution containing the water-insoluble or hardly water-soluble drug and phospholipid in an organic solvent with an aqueous solvent, emulsifying the resultant mixture and removing the organic solvent from the emulsion thus obtained to form a phospholipid coating film on the surface of the water-insoluble or hardly water-soluble drug.

Abstract: An improved electrical connector has a series of terminals arranged in two parallel rows in the connector housing, with the terminals being separated into upper and lower levels. The tail portions of the upper terminals have intermediate portions that are bent down to descend obliquely from the rear side of the connector housing while the tail portions of the lower terminals have corresponding intermediate portions that are bent up to rise obliquely from the rear side of the connector housing. The intermediate portions of the upper and lower rows of terminals meet with the solder tail portions of the tail portions along a common length so that the tail portions of both upper and lower rows have the same electrical length. The intermediate portions of both rows of terminals are also tapered, or flared along their length so that they have a larger surface area where they exit the connector housing than where they join to their associated solder tail portions.

Abstract: A thermal transfer recording medium for forming a color image by superimposingly transferring plural different color inks, comprising a foundation and a first and second color ink layer provided on the foundation, and a first and second release layer comprising a wax interposed between the foundation and the respective color ink layers, wherein the heat of fusion C1 of the release layer for a first color and the heat of fusion C2 of the release layer for a second color satisfy the relationship represented by formula (I): C1<C2  (I).